FY 2026 marked a significant inflection point for Aspen as the Group delivered strong normalised earnings growth, improved profitability across both Commercial Pharmaceuticals and Manufacturing, and successfully completed the APAC divestment.
Aspen Pharmacare Holdings Limited (“Aspen”) today announced the successful completion of the divestment of its Asia Pacific (“APAC”) business comprising Australia, New Zealand and other Asia Pacific regions (excluding China)
Aspen Pharmacare Holdings has reported unaudited Group interim financial results for the six months ended 31 December 2025.
Aspen Holdings, through its wholly owned subsidiary Aspen Global Incorporated, has entered into binding agreements for the 100% sale of Aspen Asia Pacific (excluding China) for R26.5 billion.
Aspen Pharmacare Holdings has reported financial results for the year ended 30 June 2025, with strong momentum in Commercial Pharmaceuticals and a modified Manufacturing strategy.
Aspen Pharmacare Holdings has reported positive Group interim financial results for the six months ended 31 December 2024.
Aspen’s Stephen Saad and Sean Capazorio will take part in Investec’s CEO conference in London from 14 to 15 November 2024.
JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has reported solid Group financial results for the year ended 30 June 2024.
Shauneen Beukes
Group Communications Consultant
+27 31 580 8600
+27 82 389 8900
sbeukes@aspenpharma.com
Our career opportunities are across the corporate spectrum, including Human Capital, Digital Technology, Legal, and Risk & Sustainability. Our employees are given the opportunity to hone their skills and develop the experience of excellence in their chosen field in the pharmaceutical industry.